BioCentury-BayHelix China Healthcare Summit - Award Winners

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2023, BayHelix and BioCentury will jointly host the BioCentury-BayHelix China Healthcare Summit (Nov. 2-3, The St. Regis Shanghai Jingan), and will present the awards in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Woman Leader of the Year. Congratulations to the 2023 BayHelix Award Winners listed below.

CONGRATULATIONS TO ALL THE 2023 AWARD WINNERS

R&D Achievement of the Year | Structure Therapeutics Inc.

R&D Achievement of the Year, recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.

CHS23 RD Achievement.jpg

Structure Therapeutics Inc. ​

Unlocking the potential of G-protein coupled receptor (GPCR) small molecules via a structure-based drug development technology platform.

Deal of the Year | Kelun and Merck/MSD

Deal of the Year, recognizing a groundbreaking pharmaceutical and/or MedTech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.​

CHS23 Deal of the Year.jpg

Kelun and Merck/MSD ​

For three cross-border collaborations where Merck licensed innovation from China’s Kelun, including a Dec. 2022 deal for seven preclinical ADCs where Kelun received $175M cash upfront, a $100M equity investment, and is eligible for up to $9.3B in milestones.​

Commercial Achievement of the Year | BeiGene

Commercial Achievement of the Year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.​

CHS23 Commerical Achievement.jpg

BeiGene ​

Brukinsa (zanubrutinib), which has become the BTKi of choice in China for treatment of B-cell malignancies. In 2023, Brukinsa received China NMPA approval for first-line treatment of CLL/SLL and WM, and the therapy is now approved in more than 65 markets in multiple indications.​

Company of the Year | Duality Biologics 

Company of the Year, recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.

CHS23 Company of the Year.jpg

Duality Biologics​

Established in 2020, China’s Duality had a landmark year in 2023 signing several collaborations for its antibody drug conjugates (ADCs), including a deal with BioNTech that included $170M upfront for two investigational assets, plus collaborations with Adcendo, and BeiGene.​

Woman Leader of the Year | Dr. Wendy Pan 

Woman Leader of the Year, recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or MedTech in China.​

CHS23 Woman Leader of the Year.jpg

Dr. Wendy Pan​

In a year marked by cross-border deals between China biotech and Western biopharma, no one stood out more than Wendy Pan, leader of the life sciences practice at Goodwin and a specialist in M&A and transactions. From Biotheus to Duality Biologics to KBP Biosciences, Wendy seemed to be working on a new deal almost every week.​

2022 Winners

For a list of 2022’s winners, please visit the 2022 China Summit web page here.

2021 Winners

For a list of 2021's winners, please visit the 2021 China Summit web page here.